Denali Therapeutics Inc. Common Stock
DNLI
Jodie situation report
Denali Therapeutics Inc. Common Stock's move is being confirmed by its market group.
DNLI accounts for 1.6% of the group's measured movement across 8.4 effective names. raw member direction is mixed; 8 of 12 session-normalized paths align to the upside. Capital-flow agreement is 17%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
No material onset for DNLI could be timestamped inside the aligned 5-minute window.
14 of 18 members in Biotech Rare Diseases are active. 0 of 8 disclosed connections are confirming.
- At least 12 of 18 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ROIV begins moving with the group.
Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.
Who this business touches
The relationships behind DNLI
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BIIBBiogen Inc.partnerMay 7, 2026 ▾
“PGRN levels in the brain with the goal of treating frontotemporal dementia ("FTD") associated with a mutation in the granulin ("GRN") gene and is being developed in collaboration with Takeda; • BIIB122/DNL151, a small molecule LRRK2 inhibitor, is being develo…”
SNYSanofipartnerMay 7, 2026 ▾
“For programs covered by collaboration agreements (including those with Takeda, Sanofi, and Biogen), we expect to commercialize only in certain geographies, as defined by the terms of the agreements with the counterpart, and rely on our partners to provide com…”
Depended on by
BIIBBiogen Inc.investeeApr 29, 2026 ▾
“The net unrealized gains recognized during the three months ended March 31, 2026, primarily reflect an increase in the aggregate fair value of our investment in Denali common stock of approximately $19.2 million.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 19 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
DNLI is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.